Cambridge Nutritional Sciences PLC (CNSL:AIM) delivered its H1 FY2026 interim results, outlining both challenges and strategic progress in advancing its personalised nutrition diagnostics business. Interim CEO James Cooper and CFO Ajay Patel reported H1 revenues of £3.9 million, below expectations due to weaker sales in Asia, the Americas, and parts of Europe, though UK and India markets saw notable growth, the latter up 33% year-on-year. Despite revenue pressure, gross margins improved to 67.7%, reflecting operational efficiencies and process improvements, while adjusted EBITDA remained positive at £0.1 million, supported by cost control. The company ended the half with £3.6 million in cash. Management highlighted ongoing sales team restructuring, a new customer success function, and investments in automation, IVDR compliance, and product innovation such as the Gut Detective test. Looking ahead, CNS expects FY2026 revenue to be below FY2025 levels but anticipates further gross margin gains and a positive adjusted EBITDA for the full year. The company targets mid-term revenue growth to £12 million and long-term ambitions of £20 million, underpinned by geographic expansion, strengthened sales execution, and scalable infrastructure. Management reaffirmed its commitment to shareholder value creation through disciplined cost management, margin enhancement, and sustained product leadership in food sensitivity and gut health diagnostics.